Annual ROE
-101.62%
+76.36%+42.90%
December 31, 2023
Summary
- As of February 7, 2025, GTBP annual return on equity is -101.62%, with the most recent change of +76.36% (+42.90%) on December 31, 2023.
- During the last 3 years, GTBP annual ROE has fallen by -197.76% (-205.70%).
- GTBP annual ROE is now -150.33% below its all-time high of 201.91%, reached on December 31, 2019.
Performance
GTBP ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly ROE
-242.22%
-81.75%-50.94%
September 30, 2024
Summary
- As of February 7, 2025, GTBP quarterly return on equity is -242.22%, with the most recent change of -81.75% (-50.94%) on September 30, 2024.
- Over the past year, GTBP quarterly ROE has dropped by -130.68% (-117.16%).
- GTBP quarterly ROE is now -128.09% below its all-time high of 862.27%, reached on December 31, 2019.
Performance
GTBP Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
ROE Formula
ROE = Net Income
Shareholders Equity ✕ 100%
Shareholders Equity ✕ 100%
GTBP ROE Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +42.9% | -117.2% |
| 3 y3 years | -205.7% | -117.1% |
| 5 y5 years | +95.5% | -117.1% |
GTBP ROE Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +61.6% | -237.2% | at low |
| 5 y | 5-year | -150.3% | +61.6% | -128.1% | +97.8% |
| alltime | all time | -150.3% | +95.5% | -128.1% | +97.8% |
GT Biopharma ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | -242.22%(+50.9%) |
| Jun 2024 | - | -160.47%(+43.9%) |
| Mar 2024 | - | -111.54%(+55.3%) |
| Dec 2023 | -101.62%(-42.9%) | -71.84%(-18.2%) |
| Sep 2023 | - | -87.80%(-21.5%) |
| Jun 2023 | - | -111.87%(+0.3%) |
| Mar 2023 | - | -111.58%(-18.6%) |
| Dec 2022 | -177.98%(-32.8%) | -137.13%(-26.9%) |
| Sep 2022 | - | -187.48%(+28.1%) |
| Jun 2022 | - | -146.33%(+17.2%) |
| Mar 2022 | - | -124.86%(-38.3%) |
| Dec 2021 | -264.78%(-375.4%) | -202.49%(-30.8%) |
| Sep 2021 | - | -292.65%(-97.3%) |
| Jun 2021 | - | -10.89 K%(-3109.5%) |
| Mar 2021 | - | 361.92%(+242.3%) |
| Dec 2020 | 96.14%(-52.4%) | 105.72%(+8.9%) |
| Sep 2020 | - | 97.04%(-59.0%) |
| Jun 2020 | - | 236.78%(-19.4%) |
| Mar 2020 | - | 293.82%(-65.9%) |
| Dec 2019 | 201.91%(-109.0%) | 862.27%(-166.4%) |
| Sep 2019 | - | -1298.87%(-41.8%) |
| Jun 2019 | - | -2230.51%(+518.8%) |
| Mar 2019 | - | -360.44%(+82.1%) |
| Dec 2018 | -2246.17%(+3824.1%) | -197.97%(+44.9%) |
| Sep 2018 | - | -136.64%(+120.2%) |
| Jun 2018 | - | -62.06%(-23.2%) |
| Mar 2018 | - | -80.84%(-34.4%) |
| Dec 2017 | -57.24%(+9.9%) | -123.25%(-56.9%) |
| Sep 2017 | - | -285.84%(-476.5%) |
| Jun 2017 | - | 75.93%(+32.1%) |
| Mar 2017 | - | 57.49%(-205.2%) |
| Dec 2016 | -52.08%(-222.5%) | -54.64%(-204.5%) |
| Sep 2016 | - | 52.30%(+25.1%) |
| Jun 2016 | - | 41.81%(-189.2%) |
| Mar 2016 | - | -46.85%(-180.5%) |
| Dec 2015 | 42.52%(-46.8%) | 58.21%(+31.4%) |
| Sep 2015 | - | 44.30%(-24.4%) |
| Jun 2015 | - | 58.63%(-67.5%) |
| Mar 2015 | - | 180.42%(+2.8%) |
| Dec 2014 | 79.88%(+885.0%) | 175.54%(+155.4%) |
| Sep 2014 | - | 68.74%(+233.9%) |
| Jun 2014 | - | 20.59%(-8.2%) |
| Mar 2014 | - | 22.43%(+149.5%) |
| Dec 2013 | 8.11%(-90.2%) | 8.99%(-44.2%) |
| Sep 2013 | - | 16.10%(-53.5%) |
| Jun 2013 | - | 34.63%(-49.2%) |
| Mar 2013 | - | 68.16%(-20.8%) |
| Dec 2012 | 82.79%(+14.1%) | 86.04%(-11.2%) |
| Sep 2012 | - | 96.93%(+27.4%) |
| Jun 2012 | - | 76.07%(+65.7%) |
| Mar 2012 | - | 45.91%(-29.9%) |
| Dec 2011 | 72.53%(+32.5%) | 65.48%(+16.6%) |
| Sep 2011 | - | 56.15%(-15.6%) |
| Jun 2011 | - | 66.53%(+37.2%) |
| Mar 2011 | - | 48.49%(-5.5%) |
| Dec 2010 | 54.76%(+39.6%) | 51.32%(-17.5%) |
| Sep 2010 | - | 62.21%(+7.9%) |
| Jun 2010 | - | 57.67%(-22.7%) |
| Mar 2010 | - | 74.65%(+54.6%) |
| Dec 2009 | 39.24%(-71.2%) | 48.30%(+34.1%) |
| Sep 2009 | - | 36.02%(-30.8%) |
| Jun 2009 | - | 52.02%(-56.7%) |
| Mar 2009 | - | 120.14%(-38.5%) |
| Dec 2008 | 136.03%(+163.4%) | 195.45%(-31.6%) |
| Sep 2008 | - | 285.69%(-131.2%) |
| Jun 2008 | - | -914.29%(-5415.6%) |
| Mar 2008 | - | 17.20%(-71.5%) |
| Dec 2007 | 51.64%(-119.5%) | 60.43%(-119.5%) |
| Sep 2007 | - | -309.64%(+6.0%) |
| Jun 2007 | - | -292.02%(-9.2%) |
| Mar 2007 | - | -321.68%(+51.3%) |
| Dec 2006 | -264.67%(+297.3%) | -212.55%(+69.3%) |
| Sep 2006 | - | -125.51%(+29.6%) |
| Jun 2006 | - | -96.84%(+25.0%) |
| Mar 2006 | - | -77.45%(+28.1%) |
| Dec 2005 | -66.62%(-17.7%) | -60.44%(+53.2%) |
| Sep 2005 | - | -39.44%(-11.2%) |
| Jun 2005 | - | -44.43%(-55.4%) |
| Mar 2005 | - | -99.55%(-48.7%) |
| Dec 2004 | -80.95% | -194.18%(-61.3%) |
| Sep 2004 | - | -501.22%(+47.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2004 | - | -339.01%(+148.4%) |
| Mar 2004 | - | -136.46%(+68.4%) |
| Dec 2003 | -75.77%(-19.3%) | -81.03%(+18.9%) |
| Sep 2003 | - | -68.17%(-5.6%) |
| Jun 2003 | - | -72.19%(+34.2%) |
| Mar 2003 | - | -53.80%(-13.0%) |
| Dec 2002 | -93.89%(-38.1%) | -61.87%(-13.0%) |
| Sep 2002 | - | -71.11%(-10.9%) |
| Jun 2002 | - | -79.84%(-54.7%) |
| Mar 2002 | - | -176.19%(-4.6%) |
| Dec 2001 | -151.76%(+9.5%) | -184.73%(+12.1%) |
| Sep 2001 | - | -164.82%(+21.5%) |
| Jun 2001 | - | -135.64%(+42.6%) |
| Mar 2001 | - | -95.12%(+2.8%) |
| Dec 2000 | -138.54%(+52.3%) | -92.49%(+22.3%) |
| Sep 2000 | - | -75.63%(-5.0%) |
| Jun 2000 | - | -79.59%(-18.5%) |
| Mar 2000 | - | -97.60%(-1.5%) |
| Dec 1999 | -90.95%(-10.4%) | -99.09%(-3.5%) |
| Sep 1999 | - | -102.71%(+2.4%) |
| Jun 1999 | - | -100.29%(+13.1%) |
| Mar 1999 | - | -88.65%(-6.5%) |
| Dec 1998 | -101.46%(+10.2%) | -94.86%(+11.7%) |
| Sep 1998 | - | -84.96%(+7.9%) |
| Jun 1998 | - | -78.72%(-21.0%) |
| Mar 1998 | - | -99.65%(+8.1%) |
| Dec 1997 | -92.04%(-32.5%) | -92.20%(-12.7%) |
| Sep 1997 | - | -105.66%(+1.5%) |
| Jun 1997 | - | -104.09%(-16.7%) |
| Mar 1997 | - | -125.00%(+1.7%) |
| Dec 1996 | -136.36%(-15.7%) | -122.92%(+1.5%) |
| Sep 1996 | - | -121.09%(-32.6%) |
| Jun 1996 | - | -179.78%(-0.7%) |
| Mar 1996 | - | -181.13%(+20.9%) |
| Dec 1995 | -161.82%(+37.3%) | -149.83%(+25.2%) |
| Sep 1995 | - | -119.70%(-6.5%) |
| Jun 1995 | - | -127.99%(+6.1%) |
| Mar 1995 | - | -120.62%(-4.8%) |
| Dec 1994 | -117.89%(+179.0%) | -126.70%(-5.4%) |
| Sep 1994 | - | -133.88%(+316.6%) |
| Jun 1994 | - | -32.14%(-36.1%) |
| Mar 1994 | - | -50.31%(+19.5%) |
| Dec 1993 | -42.25%(+526.9%) | -42.11%(+3.9%) |
| Sep 1993 | - | -40.54%(+51.1%) |
| Jun 1993 | - | -26.83%(+295.7%) |
| Mar 1993 | - | -6.78%(-24.2%) |
| Dec 1992 | -6.74%(+58.2%) | -8.94%(+35.7%) |
| Sep 1992 | - | -6.59%(+1.1%) |
| Jun 1992 | - | -6.52%(0.0%) |
| Mar 1992 | - | -6.52%(+51.6%) |
| Dec 1991 | -4.26%(-120.6%) | -4.30%(-303.8%) |
| Sep 1991 | - | 2.11%(-49.4%) |
| Jun 1991 | - | 4.17%(-71.4%) |
| Mar 1991 | - | 14.58%(-48.1%) |
| Dec 1990 | 20.69%(+4.9%) | 28.09%(+21.7%) |
| Sep 1990 | - | 23.08%(+12.5%) |
| Jun 1990 | - | 20.51%(0.0%) |
| Mar 1990 | - | 20.51%(+14.3%) |
| Dec 1989 | 19.72%(+522.1%) | 17.95%(-4.3%) |
| Sep 1989 | - | 18.75%(0.0%) |
| Jun 1989 | - | 18.75%(+99.9%) |
| Mar 1989 | - | 9.38%(+199.7%) |
| Dec 1988 | 3.17%(-68.8%) | 3.13%(-51.5%) |
| Sep 1988 | - | 6.45%(+99.7%) |
| Jun 1988 | - | 3.23%(>+9900.0%) |
| Mar 1988 | - | 0.00%(-100.0%) |
| Dec 1987 | 10.17%(-175.0%) | 6.45%(-190.3%) |
| Sep 1987 | - | -7.14%(0.0%) |
| Jun 1987 | - | -7.14%(-50.0%) |
| Mar 1987 | - | -14.29%(+11.9%) |
| Dec 1986 | -13.56%(+49.2%) | -12.77%(+31.9%) |
| Sep 1986 | - | -9.68%(+199.7%) |
| Jun 1986 | - | -3.23%(<-9900.0%) |
| Mar 1986 | - | 0.00%(-100.0%) |
| Dec 1985 | -9.09%(-256.7%) | -9.68%(<-9900.0%) |
| Sep 1985 | - | 0.00%(-100.0%) |
| Jun 1985 | - | -2.86%(-200.0%) |
| Mar 1985 | - | 2.86%(-49.9%) |
| Dec 1984 | 5.80%(-34.2%) | - |
| Dec 1984 | - | 5.71% |
| Feb 1984 | 8.82% | - |
FAQ
- What is GT Biopharma annual return on equity?
- What is the all time high annual ROE for GT Biopharma?
- What is GT Biopharma annual ROE year-on-year change?
- What is GT Biopharma quarterly return on equity?
- What is the all time high quarterly ROE for GT Biopharma?
- What is GT Biopharma quarterly ROE year-on-year change?
What is GT Biopharma annual return on equity?
The current annual ROE of GTBP is -101.62%
What is the all time high annual ROE for GT Biopharma?
GT Biopharma all-time high annual return on equity is 201.91%
What is GT Biopharma annual ROE year-on-year change?
Over the past year, GTBP annual return on equity has changed by +76.36% (+42.90%)
What is GT Biopharma quarterly return on equity?
The current quarterly ROE of GTBP is -242.22%
What is the all time high quarterly ROE for GT Biopharma?
GT Biopharma all-time high quarterly return on equity is 862.27%
What is GT Biopharma quarterly ROE year-on-year change?
Over the past year, GTBP quarterly return on equity has changed by -130.68% (-117.16%)